Tetsuya Nakagiri

Hiroshima, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Hepatic Carcinoma With Epithelial-Myoepithelial Differentiation and Metachronous Intrahepatic Recurrence Following Curative Resection: A Rare Case Report.

Hepatic Carcinoma With Epithelial-Myoepithelial Differentiation and Metachronous Intrahepatic Recurrence Following Curative Resection: A Rare Case Report.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: April 20, 2026

Durvalumab and tremelimumab combination therapy achieved remarkable response in primary hepatic undifferentiated carcinoma with high PD-L1 expression.

Durvalumab and tremelimumab combination therapy achieved remarkable response in primary hepatic undifferentiated carcinoma with high PD-L1 expression.

Journal: Clinical journal of gastroenterology

Published: December 08, 2025

Merlin Immunohistochemistry Is Useful in the Differential Diagnosis of Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia.

Merlin Immunohistochemistry Is Useful in the Differential Diagnosis of Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia.

Journal: Pathology international

Published: October 07, 2025

Diagnostic performance of TILs-US score and LPBC in biopsy specimens for predicting pathological complete response in patients with breast cancer.

Diagnostic performance of TILs-US score and LPBC in biopsy specimens for predicting pathological complete response in patients with breast cancer.

Journal: International journal of clinical oncology

Published: June 14, 2024

Reply to "Correspondence: SPARC, HEG1, and the Diagnosis of Epithelioid Mesothelioma" by Churg et al.

Reply to "Correspondence: SPARC, HEG1, and the Diagnosis of Epithelioid Mesothelioma" by Churg et al.

Journal: The American journal of surgical pathology

Published: February 15, 2024

SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma.

SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma.

Journal: The American journal of surgical pathology

Published: October 30, 2023

Long Non-coding RNA LINC00152 Requires EZH2 to Promote Mesothelioma Cell Proliferation, Migration, and Invasion.

Long Non-coding RNA LINC00152 Requires EZH2 to Promote Mesothelioma Cell Proliferation, Migration, and Invasion.

Journal: Anticancer research

Published: October 19, 2023

FOXM1 Promotes Mesothelioma Cell Migration and Invasion via Activation of SMAD Signaling.

FOXM1 Promotes Mesothelioma Cell Migration and Invasion via Activation of SMAD Signaling.

Journal: Anticancer research

Published: June 07, 2023

miR-142-3p Suppresses Invasion and Adhesion of Mesothelioma Cells by Downregulating ITGAV.

miR-142-3p Suppresses Invasion and Adhesion of Mesothelioma Cells by Downregulating ITGAV.

Journal: Pathobiology : journal of immunopathology, molecular and cellular biology

Published: October 03, 2022

Insulin-Like Growth Factor 2 mRNA Binding Protein 3 Promotes Cell Proliferation of Malignant Mesothelioma Cells by Downregulating p27Kip1.

Insulin-Like Growth Factor 2 mRNA Binding Protein 3 Promotes Cell Proliferation of Malignant Mesothelioma Cells by Downregulating p27Kip1.

Journal: Frontiers in oncology

Published: October 15, 2021

Showing 1-10 of 10

Last Updated: 09/26/2026